Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 2000
Single User License Price INR 143840
Corporate User License Price USD 6000
Corporate User License Price INR 431520
Site License Price USD 4000
Site License Price INR 287680
Request a Quote

Report Title

Hemophilia A - Pipeline Review, H2 2018

Quote Request for License Type
License Type Price  
Single User License USD 2000
Site License USD 4000
Enterprise Wide License USD 6000
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Hemophilia A - Pipeline Review, H2 2018


Quote Request for License Type
License Type Price  
Single User License USD 2000
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Hemophilia A - Pipeline Review, H2 2018

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Hemophilia A - Pipeline Review, H2 2018



Executive Summary

Hemophilia A-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hemophilia A-Pipeline Review, H2 2018, provides an overview of the Hemophilia A (Hematological Disorders) pipeline landscape.

Hemophilia A is an X-linked, recessive disorder caused by deficiency of functional plasma clotting factor VIII (FVIII), which may be inherited or arise from spontaneous mutation. Depending on the level of FVIII activity, patients with hemophilia may present with easy bruising, inadequate clotting of traumatic injury or in the case of severe hemophilia spontaneous hemorrhage. Symptoms may include bleeding into joints, with associated pain and swelling, blood in the urine or stool, bruising, gastrointestinal tract and urinary tract hemorrhage, nosebleeds, prolonged bleeding from cuts, tooth extraction, and surgery and spontaneous bleeding.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hemophilia A-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Hemophilia A (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hemophilia A (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hemophilia A and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 9, 9, 2, 2, 26, 6 and 2 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 3 molecules, respectively.

Hemophilia A (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Hemophilia A (Hematological Disorders).

- The pipeline guide reviews pipeline therapeutics for Hemophilia A (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Hemophilia A (Hematological Disorders) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Hemophilia A (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Hemophilia A (Hematological Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Hemophilia A (Hematological Disorders).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Hemophilia A (Hematological Disorders) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents 2

Introduction 5

Hemophilia A-Overview 6

Hemophilia A-Therapeutics Development 7

Hemophilia A-Therapeutics Assessment 18

Hemophilia A-Companies Involved in Therapeutics Development 26

Hemophilia A-Drug Profiles 45

Hemophilia A-Dormant Projects 164

Hemophilia A-Discontinued Products 166

Hemophilia A-Product Development Milestones 167

Appendix 178

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

Number of Products under Development for Hemophilia A, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Targets, H2 2018

Number of Products by Stage and Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Top 10 Molecule Types, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2 2018

List of Tables

Number of Products under Development for Hemophilia A, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Hemophilia A-Pipeline by Amarna Therapeutics BV, H2 2018

Hemophilia A-Pipeline by Apitope International NV, H2 2018

Hemophilia A-Pipeline by Bayer AG, H2 2018

Hemophilia A-Pipeline by Beijing Tiantan Biological Products Co Ltd, H2 2018

Hemophilia A-Pipeline by BioMarin Pharmaceutical Inc, H2 2018

Hemophilia A-Pipeline by Bioverativ Inc, H2 2018

Hemophilia A-Pipeline by Casebia Therapeutics, H2 2018

Hemophilia A-Pipeline by Catalyst Biosciences Inc, H2 2018

Hemophilia A-Pipeline by Chugai Pharmaceutical Co Ltd, H2 2018

Hemophilia A-Pipeline by CSL Ltd, H2 2018

Hemophilia A-Pipeline by Daiichi Sankyo Co Ltd, H2 2018

Hemophilia A-Pipeline by DBV Technologies SA, H2 2018

Hemophilia A-Pipeline by EpiVax Inc, H2 2018

Hemophilia A-Pipeline by Expression Therapeutics LLC, H2 2018

Hemophilia A-Pipeline by GC Pharma, H2 2018

Hemophilia A-Pipeline by ID Pharma Co Ltd, H2 2018

Hemophilia A-Pipeline by Idogen AB, H2 2018

Hemophilia A-Pipeline by Immusoft Corp, H2 2018

Hemophilia A-Pipeline by Innovare R & D SA De CV, H2 2018

Hemophilia A-Pipeline by LFB SA, H2 2018

Hemophilia A-Pipeline by Novo Nordisk AS, H2 2018

Hemophilia A-Pipeline by Octapharma AG, H2 2018

Hemophilia A-Pipeline by Okklo Life Sciences BV, H2 2018

Hemophilia A-Pipeline by OPKO Biologics Ltd, H2 2018

Hemophilia A-Pipeline by Pangen Biotech Inc., H2 2018

Hemophilia A-Pipeline by Pfizer Inc, H2 2018

Hemophilia A-Pipeline by Pharming Group NV, H2 2018

Hemophilia A-Pipeline by Promethera Biosciences SA, H2 2018

Hemophilia A-Pipeline by Recursion Pharmaceuticals Inc, H2 2018

Hemophilia A-Pipeline by Sangamo Therapeutics Inc, H2 2018

Hemophilia A-Pipeline by Sanofi, H2 2018

Hemophilia A-Pipeline by Shire Plc, H2 2018

Hemophilia A-Pipeline by Sino Biopharmaceutical Ltd, H2 2018

Hemophilia A-Pipeline by SK Chemicals Co Ltd, H2 2018

Hemophilia A-Pipeline by Spark Therapeutics Inc, H2 2018

Hemophilia A-Pipeline by Ultragenyx Pharmaceutical Inc, H2 2018

Hemophilia A-Pipeline by UniQure NV, H2 2018

Hemophilia A-Pipeline by XL-protein GmbH, H2 2018

Hemophilia A-Dormant Projects, H2 2018

Hemophilia A-Discontinued Products, H2 2018

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Amarna Therapeutics BV

Apitope International NV

Bayer AG

Beijing Tiantan Biological Products Co Ltd

BioMarin Pharmaceutical Inc

Bioverativ Inc

Casebia Therapeutics

Catalyst Biosciences Inc

Chugai Pharmaceutical Co Ltd

CSL Ltd

Daiichi Sankyo Co Ltd

DBV Technologies SA

EpiVax Inc

Expression Therapeutics LLC

GC Pharma

ID Pharma Co Ltd

Idogen AB

Immusoft Corp

Innovare R & D SA De CV

LFB SA

Novo Nordisk AS

Octapharma AG

Okklo Life Sciences BV

OPKO Biologics Ltd

Pangen Biotech Inc.

Pfizer Inc

Pharming Group NV

Promethera Biosciences SA

Recursion Pharmaceuticals Inc

Sangamo Therapeutics Inc

Sanofi

Shire Plc

Sino Biopharmaceutical Ltd

SK Chemicals Co Ltd

Spark Therapeutics Inc

Ultragenyx Pharmaceutical Inc

UniQure NV

XL-protein GmbH

Hemophilia A Therapeutic Products under Development, Key Players in Hemophilia A Therapeutics, Hemophilia A Pipeline Overview, Hemophilia A Pipeline, Hemophilia A Pipeline Assessment


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand